文献速递甲状腺疾病

年龄、ATA风险分组与治疗反应是儿童分化型甲状腺癌的预后因素

Age, American Thyroid Association Risk Group, and Response to Therapy Are Prognostic Factors in Children With Differentiated Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该研究基于德国儿科肿瘤血液恶性内分泌肿瘤登记处1995年以来登记的354例18岁以下分化型甲状腺癌患者,回顾性分配ATA风险组并评估治疗反应。中位诊断年龄13.7岁,淋巴结转移占74.3%,远处转移占24.5%,十年总生存率98.9%、无事件生存率78.1%。多因素分析显示诊断年龄<10岁、ATA高危组和治疗反应差是无事件生存的显著负性预后因素。

要点

  • 儿童分化型甲状腺癌淋巴结转移和远处转移率高,但总生存率仍优秀。
  • 诊断年龄<10岁、ATA高危组、治疗反应差是无事件生存的独立负性预后因素。
  • 需根据年龄、ATA风险组和治疗反应进行风险适配的个体化治疗与随访。

核心结论

  • 年龄<10岁、ATA高危风险组和治疗反应差是儿童分化型甲状腺癌无事件生存的显著负性预后因素。

研究设计与样本

  • 回顾性分析德国儿科肿瘤血液恶性内分泌肿瘤登记处自1995年以来登记的354例18岁以下原发分化型甲状腺癌患者。
  • 患者被回顾性分配至美国甲状腺协会(ATA)风险组并评估治疗反应。

主要发现

  • 诊断时中位年龄13.7岁(范围3.6-17.9岁),淋巴结转移占74.3%,远处转移占24.5%。
  • 平均随访4.1年(范围0-20.6年),十年总生存率为98.9%,无事件生存率为78.1%。
  • 淋巴结转移和远处转移(P < .001)、术后甲状腺球蛋白阳性(P = .006)、切除不完全(P = .002)、为完成全甲状腺切除的多次手术(P = .042)、包膜侵犯(P < .001)和淋巴管侵犯(P = .005)、周围软组织浸润(P < .001)、肿瘤多灶性(P < .001)、ATA中危和高危组(P < .001)、年龄<10岁(P < .001)均与无事件生存率降低相关。
  • 多因素分析显示诊断年龄<10岁、ATA高危水平和治疗反应差是无事件生存的显著负性预后因素。

临床怎么用

  • 儿童分化型甲状腺癌患者应结合诊断年龄、ATA风险分组和治疗反应进行风险适配的个体化治疗与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Against the background of increasing incidence, pediatric differentiated thyroid carcinoma (DTC) frequently presents with advanced disease and high recurrence rates while prognosis remains excellent. BACKGROUND: We investigated the use of a pediatric classification and an adult response to therapy risk stratification for pediatric DTC patients and their implications for adaptation of treatment and follow-up. METHODS: Data from patients aged <18 years with a diagnosis of primary DTC, registered with the German Pediatric Oncology Hematology-Malignant Endocrine Tumor registry since 1995, were analyzed. For risk prediction, patients were retrospectively assigned to the American Thyroid Association (ATA) risk groups and evaluated for response to therapy. RESULTS: By October 2019, 354 patients with DTC had been reported (median age at diagnosis 13.7 years, range 3.6-17.9) with lymph node and distant metastases in 74.3% and 24.5%. Mean follow-up was 4.1 years (range 0-20.6). Ten-year overall and event-free survival (EFS) rates were 98.9% and 78.1%. EFS was impaired for patients with lymph node and distant metastases (P < .001), positive postoperative thyroglobulin (P = .006), incomplete resection (P = .002), sequential surgeries to achieve total thyroidectomy (P = .042), invasion of capsule (P < .001) and lymph vessels (P = .005), infiltration of surrounding soft tissues (P < .001), tumor multifocality (P < .001), ATA intermediate- and high-risk group (P < .001), and age <10 years (P < .001). Multivariate analysis revealed age <10 years at diagnosis, ATA high-risk level, and poor response to therapy as significant negative prognostic factors for EFS. CONCLUSION: Age, ATA risk group, and response to therapy emerged as significant prognostic factors for EFS in pediatric patients with DTC, requiring risk-adapted individualized therapy and follow-up.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Redlich A, Luster M, Lorenz K, et al. Age, American Thyroid Association Risk Group, and Response to Therapy Are Prognostic Factors in Children With Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022. PMID: 34415989. doi:10.1210/clinem/dgab622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。